Promega and Celsis In Vitro Technologies to offer more reliable solutions for ADME/Tox testing in primary hepatocytes
MADISON, Wis.--Promega Corp. and Baltimore, Md.-based Celsis In Vitro Technologies (Celsis IVT) will take the trial and guess work out of ADME/Tox testing in primary hepatocytes. Promega will co-market their bioluminescent ADME-Tox assays with Celsis’ extensive line of high quality cryopreserved plateable hepatocytes. Under the...